Tocqueville Asset Management L.P. decreased its stake in shares of Sanofi (NYSE:SNY) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 209,750 shares of the company’s stock after selling 5,980 shares during the period. Tocqueville Asset Management L.P.’s holdings in Sanofi were worth $10,443,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Pennsylvania Trust Co increased its position in Sanofi by 0.4% during the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after buying an additional 37 shares in the last quarter. Moors & Cabot Inc. grew its position in shares of Sanofi by 0.7% in the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock valued at $311,000 after purchasing an additional 43 shares during the period. Rehmann Capital Advisory Group grew its position in shares of Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after purchasing an additional 47 shares during the period. Strategic Global Advisors LLC grew its position in shares of Sanofi by 0.6% in the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after purchasing an additional 54 shares during the period. Finally, First City Capital Management Inc. grew its position in shares of Sanofi by 0.3% in the second quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock valued at $1,839,000 after purchasing an additional 100 shares during the period. 9.35% of the stock is owned by institutional investors.
Sanofi (SNY) traded down $0.46 during mid-day trading on Friday, reaching $45.74. The company’s stock had a trading volume of 805,447 shares, compared to its average volume of 1,380,000. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65. The stock has a market capitalization of $115.82 billion, a P/E ratio of 14.58, a PEG ratio of 2.04 and a beta of 0.88.
A number of brokerages have recently commented on SNY. Cowen and Company reaffirmed a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Finally, Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $53.50.
In other news, major shareholder Sanofi purchased 105,820 shares of the stock in a transaction on Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.00% of the stock is currently owned by insiders.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.